SCHEMBL4278530

SCHEMBL4278530

C=C(CC(=O)C1CO1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TET2 Q6N021 3/20 0.31
TET3 O43151 1/20 0.31
TET1 Q8NFU7 1/20 0.31
GRIK1 P39086 1/20 0.30
GRIK2 Q13002 1/20 0.30
GRM1 Q13255 1/20 0.30
GRM2 Q14416 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7714154 0.79 TDP1 (0.38) ALOX15HSD17B10
Itaconate SCHEMBL27534510 0.74 ALOX15 (0.48) ALOX15HSD17B10
Itaconate SCHEMBL7044038 0.71 ALOX15 (0.46) ALOX15HSD17B10
Itaconate SCHEMBL27584099 0.71 ALOX15 (0.68) ALOX15HSD17B10TET2TET3TET1
Itaconate SCHEMBL29886131 0.70
Itaconate SCHEMBL286967 0.70 ALOX15 (0.75) ALOX15HSD17B10TET2TET3TET1
Itaconate SCHEMBL21523 0.70
SCHEMBL12808169 0.70
SCHEMBL1809603 0.69 ALOX15 (0.57) ALOX15HSD17B10TET2TET3TET1
SCHEMBL643273 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11045833-B2 Task specific ionic liquid-impregnated polymeric surface coatings for antibacterial, antifouling, and metal scavenging activity MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-06-29 US disclosed
US-9273354-B2 System and apparatus for sequential processing of analytes ILLUMINA, INC. (US) 2016-03-01 US disclosed
CN-104398496-A Once-a-day replacement transdermal administration of fentanyl ALZA CORP 2015-03-11 CN disclosed
CN-101902996-B Once-a-day replacement transdermal administration of fentanyl ALZA CORP 2014-11-26 CN disclosed
US-20140213464-A1 SYSTEM AND APPARATUS FOR SEQUENTIAL PROCESSING OF ANALYTES ILLUMINA, INC. (US) 2014-07-31 US disclosed
US-8728729-B2 Method for sequential sequencing nucleic acids ILLUMINA, INC. (US) 2014-05-20 US disclosed
US-20130184162-A1 SYSTEM AND APPARATUS FOR SEQUENTIAL PROCESSING OF ANALYTES ILLUMINA, INC. (US) 2013-07-18 US disclosed
CN-101351335-B Multilayer fluoropolymer films ARKEMA INC 2013-05-15 CN disclosed
US-8361713-B2 System and apparatus for sequential processing of analytes ILLUMINA, INC. (US) 2013-01-29 US disclosed
CN-101902996-A Once-a-day replacement transdermal administration of fentanyl ALZA CORP 2010-12-01 CN disclosed
US-6406848-B1 MICROPARTICLES AND POLYNUCLEOTIDES LYNX THERAPEUTICS, INC. 2002-06-18 US disclosed
US-20020061529-A1 System and apparatus for sequential processing of analytes LYNX THERAPEUTICS, INC. (US) 2002-05-23 US disclosed
US-20020051992-A1 Device for the analysis and monitoring of multiple samples on a solid support LYNX THERAPEUTICS, INC. (US) 2002-05-02 US disclosed
EP-1017847-A1 METHOD OF MAPPING RESTRICTION SITES IN POLYNUCLEOTIDES LYNX THERAPEUTICS, INC. (US) 2000-07-12 EP disclosed
EP-0985142-A2 SYSTEM AND APPARAUS FOR SEQUENTIAL PROCESSING OF ANALYTES LYNX THERAPEUTICS, INC. (US) 2000-03-15 EP disclosed
CN-1230226-A Sequencing by ligation of encoded adaptors LYNX THERAPEUTICS INC (US) 1999-09-29 CN disclosed
EP-0923650-A1 SEQUENCING BY LIGATION OF ENCODED ADAPTORS LYNX THERAPEUTICS, INC. (US) 1999-06-23 EP disclosed
WO-1999000519-A1 METHOD OF MAPPING RESTRICTION SITES IN POLYNUCLEOTIDES LYNX THERAPEUTICS, INC. (US) 1999-01-07 WO disclosed
WO-1998053300-A2 SYSTEM AND APPARAUS FOR SEQUENTIAL PROCESSING OF ANALYTES LYNX THERAPEUTICS, INC. (US) 1998-11-26 WO disclosed
WO-1997046704-A1 SEQUENCING BY LIGATION OF ENCODED ADAPTORS LYNX THERAPEUTICS, INC. (US) 1997-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11045833-B2 Task specific ionic liquid-impregnated polymeric surface coatings for antibacterial, antifouling, and metal scavenging activity LPO, SOD1, ICMT ALOX15 49/4885HSD17B10 811/4885TET2 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.